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PART A: PROTOCOL 
 
Heroin Detoxification during Pregnancy 
A retrospective study and a systematic review 
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There is a widely-held view that opiate withdrawal should be avoided during 
pregnancy, although if it is undertaken, this should be done with caution 
between 14 and 32 weeks gestation. This view is largely the result of two 
influential case reports published in the 1970s. Rementena and Nunang 
described a case study of a stillbirth at term following acute methadone 
withdrawal,1 and Zuspan et al  described a case report of increased amniotic 
fluid epinephrine levels during methadone withdrawal, which resolved once 
the methadone dose was increased.2 
These initial concerns have since been challenged. However, large-scale 
evidence-based data is still lacking in this field. Luty et al conducted a 
retrospective study in 2003, which reviewed 101 case reports of methadone 
withdrawal conducted at various stages of pregnancy. They concluded that 
detoxification treatment was not associated with any risk of miscarriage in the 
second trimester or premature delivery in the third trimester. While there was 
an increased risk of miscarriage in the first trimester, these results were not 
statistically significant.3 
There are several options available in the treatment of heroin dependence 
during pregnancy. These include methadone or buprenorphine maintenance 
throughout the pregnancy, medication-assisted withdrawal using methadone 
or other opiates, and withdrawal using non-opiate symptomatic medications 
such as clonidine, other benzodiazepines and analgesics.4 Naltrexone has 











pregnancy after being successfully used in non-pregnant heroin users to 
discourage further illicit heroin use.5
Methadone hydrochloride is a synthetic opiate with pharmacological 
properties similar to morphine. It is a full mu opiate agonist with a prolonged 
duration of action (24 – 48 hrs). Because of its oral availability, long duration 
of action and cross-tolerance with other opiates, it is a useful agent in the 
maintenance treatment of heroin addicts. In 1965 Dole and Nyswander 
published a report advocating the use of methadone in opiate withdrawal. 
Since then it has been the primary maintenance agent used for heroin 
addicts, including pregnant women.6
Buprenorphine has recently been used as an alternative agent to methadone. 
It also reduces withdrawal symptoms and heroin cravings, but has lower 
sedative and euphoric effects. These differences are due to the fact that it is 
only a partial mu receptor agonist, and is also a kappa receptor antagonist. 
However, it is currently still classified as a Category C drug, which is contra-
indicated in pregnancy and lactation. Virginia and William conducted a study 
in 2004 in which they successfully treated twenty heroin-dependent pregnant 
women with buprenorphine. No adverse effects were reported, and they 
therefore suggested that the Category C classification be reviewed.7
Methadone maintenance is currently still viewed as the gold standard of 
management of pregnant heroin users. This is primarily based on the fact that 
mothers engaged in maintenance programmes are less likely to use illicit 
drugs or to engage in other maternal risk behaviours. There is also improved 











been shown to secondarily improve neonatal outcomes, measured by overall 
heavier birth weights.8 
However, maintenance management with methadone poses its own risks. 
Methadone dependence at birth has been associated with fetal death, growth 
restriction, pre-term birth, meconium aspiration and neonatal abstinence 
syndrome.3 This syndrome has been shown to be worse in patients treated 
with high doses of methadone (>20 micrograms/ day) than in untreated heroin 
addicts. Therefore, it is recommended that patients be placed on a low dose 
regime (<20micrograms/ day) at least one month prior to delivery.6 
Methadone withdrawal is the standard management of pregnant heroin 
addicts in state hospitals in South Africa. This is largely due to financial 
constraints, as methadone maintenance management is more costly than 
withdrawal. This concept has, however, been challenged by Daley et al who 
suggest that the health care costs should not be viewed in isolation. They 
argue that maintenance treatment reduces maternal criminal behaviour by 
reducing illicit drug use, which has secondary cost implications to society. The 
authors conducted a study in Massachusetts, USA, which showed that the 
cost of crime far outweighed that of substance abuse treatment. In patient 
methadone maintenance showed the greatest cost-benefit ratio, which 
supports the view of methadone maintenance being the gold-standard 
treatment.9 
South Africa is currently experiencing a widespread surge in heroin use. It is 











opiate withdrawal in state hospitals, and to enquire whether they should be 
managed differently. 
 
Aims and Objectives 
1. To conduct a retrospective review of all pregnant heroin-addicted patients 
who have been detoxified at Groote Schuur Hospital (GSH) in the last five 




All pregnant patients who were detoxified at GSH between 2005 and 2009. 
GSH is a tertiary state hospital located in Cape Town. All these patients are 
managed in the acute psychiatric ward (C23).  
Identification of cases 
C23 keeps a register of all patients who have received methadone. 
Identification of the patients treated during this period is carried out by 
information obtained from the methadone register.  
Not all patients who are detoxified receive methadone. Therefore, an 
examination of all the discharge summaries of patients over this period will be 











Information will be extracted from the files. The following, in particular, will be 
looked at: 
• Maternal age 
• Stage of pregnancy, i.e. gestational age 
• Quantity of heroin used by mother 
• Other illicit substance use 
• Course of detoxification at C23, and what drugs were used 
• Obstetric outcomes, including intra-uterine deaths (stillbirths and 
miscarriages), preterm delivery, birth weight, APGAR scores. 
 
Statistical Methods 
 Information obtained will be captured, processed and summarised by means 
of a computer data analysis program (SPSS version 17.0). Descriptive 
statistics will be used to characterise the sample.  
 
Systematic review 
The electronic database Medline will be searched using a combination of the 
following search terms: pregnancy, heroin, opiate, methadone, 
buprenorphine, treatment. Additional publications will be identified from the 
reference lists of retrieved articles. All relevant articles in English reporting 














Only information that is relevant to the study will be extracted from the patient 
files, i.e. no additional data will be recorded. The data that is extracted will be 
recorded on numbered forms. Only the primary researcher will hold the codes 
which correlate the data on the forms with the individual cases. All the data 
will be de-identified. Patients will be referred to solely by means of letters of 
the alphabet when individual cases are described.  
As this is a retrospective study, patient consent is not provided. 
The study will be submitted to the ethics committee for approval. 
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PART B: LITERATURE REVIEW 
Objectives of literature review 
• To conduct a systematic review of the literature in order to assess
current knowledge of the management of heroin addiction in pregnancy
• To identify key studies already performed in this field of research
• To determine whether there are any specific gaps in the knowledge, 
and whether there is a need for further research
• To identify limitations in previous studies and directions for future work.
Literature search strategy
The search was conducted using the electronic database PubMed. This is a 
well-established repository of peer-reviewed research articles pertaining to the 
life sciences. 
The following key words were used in the search: pregnancy, heroin, opiate, 
methadone, buprenorphine, treatment. Additional publications were identified 
by hand-searching the reference lists of retrieved articles. 
All relevant articles in English, reporting original data related to the treatment 
of heroin addiction in pregnancy were included. The search was not restricted 











literature search was initially conducted in May 2011, and was revised in June 
2012. 
Using the terms described above, 12 English articles were located on a 
Pubmed search. Of these articles, 3 were relevant to the study. However, by 




Summary of literature 
Introduction 
Diacetylmorphine was first synthesised in 1874 as a highly potent, acetylated 
form of morphine. However, it was only a few years later, in1898, that Bayer 
pharmaceutical company first marketed this drug under the trademark name 
of Heroin. It was initially sold as a non-addictive morphine substitute and 
cough suppressant. However, heroin was soon found to be twice as powerful 
as morphine, due to the fact that it is highly fat-soluble and rapidly crosses the 
blood-brain barrier. As a result of this finding, the United States Congress 
banned its sale in 1924, and heroin is now classified as a schedule 1 drug, 
which makes its use illegal for non-medical purposes. 
Despite these stricter controls, heroin remains the most widely used opiate. In 
2009, there were an estimated 12–14 million heroin users worldwide. Europe 











is, according to reports, increasing.1 In South Africa, heroin appears to be 
used primarily by people between the ages of 21 to 24 years. According to a 
review by Parry et al in 2003, approximately 20–40% of people treated for 
heroin abuse in South Africa are female, which is a higher percentage than 
that for most other illicit substances.2 
Opiate use is associated with menstrual irregularities, which, when added to 
the often erratic lifestyles of drug-abusing women, leads to a high rate of 
unplanned pregnancies. A significant proportion of the heroin-dependent 
population is comprised of women of childbearing age, and there are now a 
growing number of heroin-addicted pregnant women in South Africa. Many of 
these women only present to medical services at the time of delivery, but 
those that present earlier usually have complex problems that require a great 
deal of care. 
 
Overview of management 
The ideal goal during pregnancy is for the mother to remain abstinent from 
any drug use. When faced with a pregnant patient who is actively abusing 
heroin, one needs to offer treatment that will best minimise any further foetal 
and maternal harm. Most of the literature suggests that opiate-dependent 
individuals are usually unable to remain drug free, and therefore require some 
form of maintenance treatment. This has led to the widely-accepted view that 











An alternative to maintenance treatment is opiate withdrawal, using 
methadone. Methadone detoxification involves using tapering doses of 
methadone in order to create a smooth transition from heroin use to a drug-
free state. Withdrawal from methadone is not generally recommended in the 
literature during pregnancy, except in specific situations. These include 
individual cases when a motivated patient expresses a wish to withdraw from 
all opiates, or when methadone maintenance is unavailable – as is the case in 
many South African public treatment facilities. 
The way patients are managed in South Africa is inconsistent with 
recommendations in the literature, a fact that necessitates further 
investigation. Hence, a systematic review on heroin detoxification in 
pregnancy was conducted, and the relevant studies are listed in the following 
table:
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A total of 18 relevant articles were found, which were reported in 13 
publications. The majority were prospective case series, but others included 
retrospective case series, case reports, literature reviews and descriptive 
studies, and there were two clinical guidelines. 
Heroin is not considered to be grossly teratogenic, but it is highly liphophilic 
and readily crosses the placenta. Untreated heroin use has been reported to 
be associated with intrauterine growth restriction, premature delivery, 
increased neonatal mortality and neonatal abstinence syndrome (NAS).5,6 The 
latter syndrome is characterised by a variety of signs and symptoms in the 
neonate, which indicate dysfunction of the autonomic nervous system, 
gastrointestinal tract and respiratory system. There is, consequently, a need 
for any kind of intervention that will reduce or eliminate maternal heroin use, in 
order to improve pregnancy outcomes.  
Maas et al published an intervention study in 1990 that compared the 
pregnancy outcomes of mothers joining a methadone detoxification 
programme to those of pregnant mothers who continued uncontrolled street 
drug use. They found that 17 women out of 58 were successfully detoxified 
during the antenatal period. The incidence of NAS was lower after maternal 
participation in the detoxification programme – 55% versus 88%. Newborns of 
mothers who had successfully detoxified experienced fewer withdrawal 
symptoms, and no adverse obstetric complications were reported in this 
group.7 This is the only intervention study that compares the pregnancy 











reduction in NAS demonstrated in this study highlights the importance of 
offering treatment to heroin-addicted pregnant women.  
According to a clinical guideline by Wong et al, withdrawal is not advised in 
the first trimester because of the potential risk of inducing abortion.3 This view 
is largely the result of an influential case report published in 1975. Zuspan et 
al described a case report of increased amniotic fluid epinephrine levels 
during methadone withdrawal, which resolved once the methadone dose was 
increased.8  
On the other hand, Winklbaur et al advise against detoxification after the 32nd 
week of pregnancy in their clinical guideline because of possible withdrawal-
induced stress.5 This recommendation is similarly based on a single case 
study by Rementeria and Nuang, also published in the 1970s, of a stillbirth at 
term following acute methadone withdrawal.9 These authors suggest that 
lowering methadone levels can induce hyper-stimulation of the adrenal gland 
and other sympathetic nervous system components, which is manifested by 
increased amniotic fluid levels of epinephrine. 
These initial concerns have since been challenged. Two studies, involving a 
total of 136 patients, showed positive pregnancy outcomes, with methadone 
withdrawal initiated at various stages of pregnancy. Dashe et al conducted a 
prospective study whereby 35 opioid-addicted pregnant patients were offered 
inpatient opiate detoxification with methadone.10 The mean gestational age of 
the patients was 24 weeks, and there was careful foetal monitoring throughout 











relapse. There was no evidence of foetal distress during detoxification, no 
foetal death, and no delivery before 36 weeks. 
Luty et al conducted a retrospective study in 2003, which reviewed 101 case 
reports of Methadone withdrawal conducted at various stages of pregnancy. 
The authors concluded that detoxification treatment was not associated with 
any risk of miscarriage in the second trimester or with premature delivery in 
the third trimester. While there was an increased risk of miscarriage in the first 
trimester as compared to the other two trimesters, these results were not 
statistically significant.11
Apart from the risk of foetal harm during methadone detoxification, the major 
concern with not providing long-term methadone treatment is an increased 
risk of relapse with ongoing illicit drug use. Continued illicit substance use is 
characterised by cycles of intoxication and withdrawal, causing a wide 
variation in blood opiate levels. This ultimately increases the risk of foetal 
distress, growth restriction and premature delivery.5
Methadone maintenance treatment, however, does not guarantee abstinence. 
Kashiwinga et al explored the pregnancy outcomes among women in a major 
Swiss methadone maintenance programme. The 84 women enrolled in the 
programme were tested for additional illicit substance use, and 64% of the 
women were found to be co-users of cocaine and/or heroin. Using birth weight 
as a measure of pregnancy outcome, the authors suggested that illicit drug 
use reversed the benefits of methadone maintenance. 12
The potential risk associated with methadone detoxification is not the primary 











care since the early 1990s.13 There is also a perception that mothers engaged 
in maintenance programmes are less likely to use illicit drugs, or to engage in 
other maternal drug-seeking behaviours, such as prostitution.14 A reduction in 
these risky behaviours will consequently reduce the woman’s chance of 
acquiring sexually transmitted diseases, HIV and hepatitis infection. 
Compliance with regular antenatal care is also assumed to improve in patients 
involved in methadone maintenance programmes. This combination of 
improved adherence to obstetric care and reduction in high-risk activities has 
been shown to secondarily improve neonatal outcomes, measured by overall 
heavier birth weights.13 
Wong et al conducted a literature review of substance abuse in pregnancy 
with the aim of providing management recommendations. The authors 
concluded that methadone maintenance treatment is associated with longer 
adherence to treatment and decreased risk of relapse to opioid use. They 
therefore proposed that the preferred standard of care for pregnant opioid-
dependant women is substitution therapy.3 
This perception has, however, been challenged. Edelin et al conducted a 
retrospective analysis of pregnant women enrolled in a methadone 
maintenance programme. The authors compared the outcomes of the 
pregnancies with a similar group of pregnant poly-drug users who were not 
involved in the maintenance programme. They found no differences in the 
birth weights or in the infants’ Apgar scores. These poor results were probably 
due to the fact that 88% of the women in the maintenance programme 











Besides not always curtailing illicit drug use, management with Methadone 
poses its own risks. Methadone dependence at birth has been associated with 
foetal death, growth restriction, pre-term birth, meconium aspiration and 
neonatal abstinence syndrome (NAS).9 It has been estimated that 60–87% of 
neonates born to methadone maintained mothers require treatment for NAS.11 
Neonates suffering from NAS grow poorly in the neonatal period, and have 
reduced height compared to controls at 3 years of age.16 
The longer-term implications of methadone maintenance treatment are also 
not clear. Hunt et al conducted a study on infants who had developed NAS, 
indicating that they had been exposed to opiates in utero. These infants had 
evidence of both cognitive and psychomotor deficit on psychometric testing, 
when compared to non-opiate-exposed controls.16 However, it is not clear 
from this study whether they had been exposed to methadone, heroin or a 
combination of opiates.  
More than 30 years ago, reports were published about abnormal ocular 
findings in infants of methadone-maintained mothers. Recent literature has re-
examined these effects, and found an increased risk of strabismus, 
nystagmus, refractive errors and delayed visual maturation. The majority of 
the infants reported in these studies had, however, been exposed to both 
opiates and benzodiazepines, so it is difficult to determine the exact 
aetiology.17 It is clear that the possibility of such long-term visual and cortical 












Methadone withdrawal is the standard management of pregnant heroin 
addicts in state hospitals in South Africa. This is largely owing to financial 
constraints, as lengthy methadone maintenance management is perceived to 
be more costly than withdrawal. This concept has, however, been challenged 
by Daley et al who suggest that the health care costs should not be viewed in 
isolation. They argue that maintenance treatment reduces maternal criminal 
behaviour by reducing illicit drug use, which has secondary cost implications 
for society. The authors conducted a study in Massachusetts, USA, which 
showed that the cost of crime far outweighed that of substance abuse 
treatment. In-patient methadone maintenance showed the greatest cost-
benefit ratio, which supports the view of methadone maintenance being the 
gold-standard treatment.18 
Two studies were conducted that examined methadone maintenance as part 
of a comprehensive care programme. Chang et al conducted a small study 
comparing the outcomes of pregnant methadone-maintained opiate-
dependent subjects in an enhanced treatment programme, with women 
receiving conventional methadone maintenance. Enhanced treatment 
consisted of weekly prenatal care, relapse prevention groups, urine toxicology 
screening with positive contingency awards for abstinence, and therapeutic 
childcare during treatment visits. The women involved in the enhanced 
treatment programme demonstrated less overall illicit drug use and delivered 
heavier infants.19 This finding was confirmed by Finnegan, who found that 
methadone maintenance in addition to intensive antenatal care is compatible 
with an uneventful pregnancy and birth of a healthy infant.20 We may also 











fluctuating maternal opiate levels, to the provision of a more comprehensive 
care package. 
Having reviewed the various studies found in the literature, what is apparent is 
that the data on the safety and efficacy of methadone detoxification is limited. 
There are, however, good data on a need to develop comprehensive 
treatment programmes that go beyond the dispensing of methadone and/or 
other medication.21 Pregnancy is known to be a useful period for encouraging 
behavioural changes. However, methadone alone, whether given as 
detoxification or maintenance, does not correct all the underlying psychosocial 
problems or address behaviour changes. The best outcomes are most likely 
to be reached by using a holistic care plan incorporating medical, psychiatric 
and social work attention. 
 
 
Identification of gaps or needs for further research 
Overall, the literature on the management of heroin addiction during 
pregnancy is extremely limited. The studies identified in this review were 
conducted on small sample sizes, were not randomised, and only a few had 
control groups. Therefore, there is a general need for more robust evidence-
based research in this field. 
The literature on the efficacy and safety of methadone detoxification is 
particularly scanty. Large-scale studies conducted at various stages of 











early case reports are indeed valid. This may help to determine whether there 
is an optimum time for detoxification to occur during the pregnancy.  
Some recent studies have raised concerns about the long-term effects of 
methadone maintenance on the infant. Given the fact that maintenance 
treatment is the current international gold standard in pregnancy, this is an 
area of research that requires urgent attention. 
No studies were found which were conducted specifically on pregnant women 
in South Africa. Research within our unique, genetically diverse population 
group is needed, specifically with regards to our policy of methadone 
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Background: There is a general consensus that methadone maintenance is 
the gold standard in the management of pregnant heroin users. However, in 
South African state hospitals, methadone withdrawal is the routine procedure 
offered to these patients, as methadone maintenance programmes are 
unavailable in the public sector. 
Objectives: (1) To conduct a systematic review of the literature on heroin 
detoxification in pregnancy and (2) to retrospectively collect data of all 
pregnant heroin users who were detoxified with methadone at Groote Schuur 
Hospital (GSH) between 2006 and 2010.  
Method: A PubMed literature search was undertaken to identify key 
publications on the management of heroin addiction in pregnancy. Patients for 
the study were identified from the GSH methadone registry, and data were 
collected from the clinical files. 
Results: A total of 18 relevant publications were identified and reviewed. Two 
case reports published in the 1970s described an increased risk of stillbirths 
and fetal distress after methadone detoxification, but two more recent case 
series involving larger numbers of patients showed positive outcomes. 
Methadone maintenance together with a social support programme was 
advocated by two clinical guidelines. Our study found that of 6 patients who 
received methadone withdrawal over a 5-year period at GSH, all of the 
neonates had good APGAR scores, did not require resuscitation, and were 











Conclusion: There is limited evidence on the management of heroin 
addiction during pregnancy, and the only two guidelines identified suggest 
that methadone maintenance is preferable to methadone withdrawal. The 
favourable pregnancy outcomes of this small sample of patients managed 
with methadone withdrawal suggests that methadone withdrawal, which is 


























Diacetylmorphine was first synthesised by C R Alder Wright in 1874 as a 
highly potent, acetylated form of morphine. By 1898, Bayer pharmaceutical 
company marketed this drug under the trademark name of Heroin. It was 
initially sold as a non-addictive morphine substitute and cough suppressant. 
However, heroin was soon found to be twice as powerful as morphine, due to 
the fact that it is highly fat-soluble and rapidly crosses the blood-brain barrier. 
Despite subsequent strict controls imposed on the use of heroin, it remains 
the most widely used opiate.1 
In 2009, there were an estimated 12–14 million heroin users worldwide.1 
Europe and Asia remain the key opiate consumption markets, but opiate use 
in Africa is, according to reports, increasing.1 The 2010 SACENDU statistics 
reveal that 5–20% of patients in specialist treatment centres in South Africa 
use heroin as their primary drug of choice. Heroin is primarily used by people 
between 22–30 years old in South Africa2, and approximately 20–40% of 
people treated for heroin abuse are female, which is a higher percentage than 
that for most other illicit substances.3 
Opiate use is associated with menstrual irregularities, which, when added to 
the often erratic lifestyles of drug-abusing women, leads to a high rate of 
unplanned pregnancies. Heroin-dependent pregnant women represent an 
extremely vulnerable group of patients, who present with various medical, 
obstetric and psychiatric problems. There has been considerable debate 
about how to best manage these patients, as the needs of both the foetus and 











The ideal goal during pregnancy is for the mother to remain abstinent from 
any drug use. When faced with a pregnant patient who is actively abusing 
heroin, one needs to offer treatment that will best minimise any further foetal 
and maternal harm. Given the highly-addictive nature of opiates, it is difficult 
for many of these individuals to remain drug free, and therefore some form of 
maintenance treatment is usually offered.  
An alternative to maintenance treatment is opiate withdrawal, using 
methadone. Methadone detoxification involves using tapering doses of 
methadone in order to create a smooth transition from heroin use to a drug-
free state. Withdrawal from methadone is not generally recommended in the 
literature during pregnancy,4-7 except in specific situations. These include 
individual cases when a motivated patient expresses a wish to withdraw from 
all opiates, or when methadone maintenance is unavailable – a situation that 
is prevalent across all South African public treatment facilities.
Due to the fact that pregnant women are rarely included in psychotropic
clinical trials, there is oft n relatively little information available about the use 
of medication during pregnancy. Therefore, the evidence-based management 
of pregnant patients who are dependent on opioids is particularly challenging. 
While guidance is scarce, the prevailing opinion is that methadone 
maintenance is the gold standard of treatment in pregnancy.4-7 This option is 
not available in South African state facilities, where only methadone 
withdrawal is offered. It would therefore be useful to review the data in the 











The specific aims of this paper are: (1) to conduct a systematic review of the 
literature on heroin detoxification in pregnancy and (2) to report on pregnancy 
outcomes of heroin users who were detoxified with methadone at GSH, a 





The electronic database PubMed was searched using a combination of the 
following search terms: pregnancy, heroin, opiate, methadone, 
buprenorphine, and treatment. Additional publications were identified from the 
reference lists of retrieved articles. All relevant articles in English, reporting 
original data related to the treatment of heroin addiction in pregnancy, were 
included. 
Using the terms described above, 12 English articles were located on a 
Pubmed search. Of these articles, 3 were relevant to the study. However, by 

















Groote Schuur Hospital is a tertiary state hospital that is situated in 
Observatory, Cape Town. The patients were managed in the labour ward or in 
C23 – the emergency psychiatric ward.  
Subjects 
The study population included all pregnant heroin-addicted patients who 
underwent methadone detoxification at GSH between 2006 and 2010. The 
labour ward and C23 keep a register of all patients who have received 
methadone.  
Data collection 
Pregnant patients treated during this period were identified by means of 
information obtained from the methadone register. Both methadone registers 
were carefully scrutinised to ensure that all pregnant patients treated at GSH 
were identified. The patients’ hospital numbers are recorded on the register, 
so it was possible to access their files with the assistance of hospital clerks. 
The outcomes of these pregnancies were then determined by looking at 
specific maternal and foetal parameters. 
Ethical considerations 
The study was approved by the University of Cape Town Human Research 
Ethics Committee, and permission was granted to access information from the 











patient files, and all the data was de-identified. As this is a retrospective study, 




A total of 18 relevant articles were found which were reported in 13 
publications. The majority were prospective case series, but others included 
retrospective case series, case reports, literature reviews and descriptive 
studies, and there were two clinical guidelines. 
 
 [TABLE 1] 
Heroin is not considered to be grossly teratogenic, but it is highly liphophilic 
and readily crosses the placenta. Untreated heroin use is associated with 
intrauterine growth restriction, premature delivery, increased neonatal 
mortality and neonatal abstinence syndrome (NAS).7,8 The latter syndrome is 
characterised by a variety of signs and symptoms in the neonate which 
indicate dysfunction of the autonomic nervous system, gastrointestinal tract 
and respiratory system. There is, consequently, a need for any kind of 
intervention that will reduce or eliminate maternal heroin use, in order to 
improve pregnancy outcomes.  
Maas et al published an intervention study in 1990 that compared the 











programme to those of pregnant mothers who continued uncontrolled street-
drug use. He found that 17 women out of 58 were successfully detoxified 
during the antenatal period. The incidence of neonatal abstinence syndrome 
was lower after maternal participation in the detoxification programme – 55% 
versus 88%. Newborns of mothers who had successfully detoxified 
experienced fewer withdrawal symptoms, and no adverse obstetric 
complications were reported in this group.9 
According to most widely-accepted recommendations, withdrawal is not 
advised before 14 weeks' gestation because of the potential risk of inducing 
abortion, and should not be performed after the 32nd week of pregnancy 
because of possible withdrawal-induced stress.5,6 This view is largely the 
result of two influential case reports published in the 1970s. Rementeria and 
Nunag described a case study of a stillbirth at term following acute 
Methadone withdrawal,10 and Zuspan et al described a case report of 
increased amniotic fluid epinephrine levels during Methadone withdrawal, 
which resolved once the Methadone dose was increased.11 
These initial concerns have since been challenged. Luty et al conducted a 
retrospective study in 2003, which reviewed 101 case reports of Methadone 
withdrawal conducted at various stages of pregnancy. They concluded that 
detoxification treatment was not associated with any risk of miscarriage in the 
second trimester or with premature delivery in the third trimester.12 Similarly, 
Dashe et al conducted a prospective study whereby 35 opioid addicted 
pregnant patients were offered inpatient opiate detoxification with methadone. 
59% of these patients were successfully detoxified, did not relapse, and had 











Apart from the risk of foetal harm during methadone detoxification, the major 
concern with not providing long-term methadone treatment is an increased 
risk of relapse to illicit drug use. There is a perception that mothers engaged 
in maintenance programmes are less likely to use illicit drugs, or to engage in 
other maternal drug-seeking behaviours, such as prostitution.  
Wong et al conducted a literature review of substance abuse in pregnancy in 
order to provide recommendations on management. The authors concluded 
that methadone maintenance treatment is associated with longer adherence 
to treatment and decreased risk of relapse to opioid use. They therefore 
proposed that the preferred standard of care for pregnant opioid-dependant 
women is substitution therapy.4 
However, some studies have shown that methadone maintenance treatment 
does not guarantee abstinence. Kashiwinga et al explored the pregnancy 
outcomes among women in a major Swiss methadone maintenance 
programme, and 64% of the women were found to be co-users of cocaine 
and/or heroin.14 
Besides not always curtailing illicit drug use, management with Methadone 
poses its own risks. Methadone dependence at birth has been associated with 
foetal death, growth restriction, pre-term birth, meconium aspiration and 
neonatal abstinence syndrome (NAS).10 It has been estimated that 60–87% of 
neonates born to methadone maintained mothers require treatment for NAS.7 
Neonates suffering from NAS grow poorly in the neonatal period, and have 











The longer-term implications of methadone maintenance treatment are also 
not clear. Hunt et al conducted a study on infants who had developed NAS, 
and found that they had evidence of both cognitive and psychomotor deficit on 
psychometric testing, when compared to non-opiate-exposed controls.15 
Recent literature has also found an increased incidence of ocular 
abnormalities in infants of methadone-maintained mothers.16 The possibility of 
long-term visual and cortical defects is alarming, and requires further 
research. 
Methadone withdrawal is the standard management of pregnant heroin 
addicts in state hospitals in South Africa. This is largely owing to financial 
constraints, as Methadone maintenance management is more costly than 
withdrawal. This concept has, however, been challenged by Daley et al who 
suggest that the health care costs should not be viewed in isolation. They 
argue that maintenance treatment reduces maternal criminal behaviour by 
reducing illicit drug use, which has secondary cost implications for society. 
The authors conducted a study in Massachusetts, USA, which indicated that 
the cost of crime far outweighed that of substance abuse treatment. 17
It seems that we need to change our focus of attention from the medical 
management of cravings and fluctuating maternal opiate levels, to providing a 
more comprehensive care package. Two studies conducted by Chang et al 
and Finnegan found that methadone maintenance, in addition to intensive 












Having reviewed the various studies found in the literature, what is apparent is 
that the data on the safety and efficacy of methadone detoxification are 
limited, There are, however, good data on a need to develop comprehensive 
treatment programmes that go beyond the dispensing of methadone and/or 
other medication.20 Pregnancy is often described as a useful period for 
encouraging behavioural changes. However, methadone alone, whether given 
as detoxification or maintenance, does not correct all the underlying 
psychosocial problems or address behaviour changes. The best outcomes 
are most likely to be reached by using an integrated care plan incorporating 
pharmacological, psychotherapeutic and social interventions.  
 
STUDY 
Due to the fact that methadone is a highly addictive schedule II drug, its 
administration is recorded in a methadone register. This register shows that 
only six pregnant heroin-addicted patients received methadone detoxification 
at GSH between 2006 and 2010. The clinical details of these patients were 
tabulated. 
[TABLE 2] 
A total of six pregnant patients received methadone withdrawal at GSH 
between 2006 and 2010. The ages of the patients ranged from 17–37 years 
old. Four of the six patients were single, and half of them had high parity. 











weeks gestation). All of the patients were HIV negative, and none had current 
syphilis infection. 
Surprisingly, none of the patients abused alcohol, and only patient F used 
another illicit substance (methamphetamine). Five of the six patients received 
methadone detoxification either at GSH or at Stikland Hospital substance 
abuse facility prior to delivery. There was no record of any psychiatric follow-
up for any of the patients after detoxification, apart from patient D who could 
afford a private rehabilitation facility. 
Four of the patients delivered at term, and patient F delivered one week short 
of term. Half of the patients required caesarean sections. Interestingly, all of 
the neonates had APGAR scores ranging between 7–10, and none of them 
required resuscitation. None of the neonates showed signs of neonatal 
abstinence syndrome. All patients were discharged from the maternity ward 
within three days after delivery. 
 
Discussion 
The main findings of our literature review indicated that there is little data on 
the safety of methadone withdrawal, and information that is available is largely 
contradictory. The most striking feature of our case series is the relatively low 
number of patients who received methadone detoxification, despite the rising 
rates of heroin use and the burden of disease encountered in Cape Town.  
Given that the 2010 SACENDU statistics reveal that heroin is the primary 











it may be speculated that heroin-addicted pregnant patients are inadequately 
screened for, or are offered detoxification with, only benzodiazepines and 
analgesics. There are two possible explanations for this. Firstly, these patients 
may face tremendous stigma, not only from their families and society, but also 
from health care providers and they may therefore be treated with little 
sympathy, being perceived as attempting to manipulate the system by 
requesting methadone treatment. Secondly, health care workers may be 
concerned about the risk of exposing the foetus to another potentially harmful 
substance. 
Five of the six patients had received methadone detoxification prior to 
delivery, while patient B went into labour during her withdrawal. Of the five 
patients who completed their detoxification, only two resumed using heroin 
prior to their delivery. In this small sample, the relapse rate is low given the 
fact that only one patient received continued psychosocial support after 
discharge. This low rate of relapse indicates that methadone detoxification 
may be a successful way of managing these patients. One of the main 
criticisms of withdrawal treatment is the high rate of relapse to heroin use, 
which was shown not to be the case in this small population. Having said this, 
a relapse rate of 40% is not negligible, and ideally, further psychosocial 
measures should be implemented to assist in maintaining abstinence. 
A major concern with methadone maintenance treatment is the high risk of the 
neonatal abstinence syndrome (NAS). This syndrome is characterised by 
central nervous system excitability in newborn infants, and in many cases 
requires pharmacological withdrawal treatment. All infants of the six patients 











APGAR scores and required no resuscitation. As mentioned earlier, the 
literature suggests that NAS requiring treatment occurs in at least two-thirds 
of infants born to mothers on methadone maintenance.8 The positive neonatal 
outcome in this group is therefore significant as it highlights a major 
advantage of methadone detoxification over maintenance. 
Remerentia and Nunag cautioned against detoxification after 32 weeks’ 
gestation due to concerns about precipitating early delivery.9 Four of the six 
patients (A, B, E and F) were detoxified after 32 weeks, and two of the four (A 
and B) went into labour during the detoxification process. This was 
problematic for patient B as it led to a premature delivery at 33 weeks. These 
findings support the view that detoxification is safest during the second 
trimester. 
An interesting finding in these six patients was the low rate of co-morbid 
substance abuse, and the fact that none of them were infected with the 
human immunodeficiency virus or with syphilis. This group of patients is 
usually at high risk for poly-substance abuse, and sexually transmitted 
infections. The absence of these common additional problems may also partly 
explain the relatively good neonatal outcomes in the group. 
What is disheartening is the apparent discrepancy in the resources available 
to heroin-addicted pregnant women in developed countries as compared to 
South Africa. The focus of most research has shifted from determining the 
merits of maintenance versus withdrawal to determining which medication is 
superior in maintenance management. South African state facilities continue 











period while undergoing withdrawal. This highlights the need for a greater 
focus on pharmacological harm reduction strategies in low and middle income 
countries. 
The limitations of the current data set include the small sample size, the 
retrospective ratings, and the lack of any follow up information. Despite this, 
however, these data suggest that favourable outcomes of pregnancies 
managed with methadone withdrawal are possible. Additional research is 
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 Title Authors Reference Type Study Summary 
1 
Maternal narcotic 












infants have higher 
rates of NAS, 
preterm delivery, 


















participation in a 
methadone detox 
programme was 
compared to street 
drug use on 
neonatal morbidity 
in 75 neonates. 
NAS occurred in 
63% of neonates, 














treatment is only 
beneficial if 
administered as part 















Description of one 








withdrawal in the 
third trimester. 
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Luty et al 












detox was not 
associated with 
adverse effects in 
the second or third 
trimester. 




858; 1998  
Prospective 
case series 
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adverse pregnancy 
outcomes, or 





























continued to use 
illicit substances 

































withdrawal alone, or 
withdrawal followed 
by maintenance. 
























become the mode of 
therapy for most 
patients based on 
early case reports. 








Review of the 
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to reduced relapse 






care and outcomes 








outcomes of 26 
narcotic-addicted 




compared to 37 
polydrug users not 
in programme. No 
major difference in 
outcomes found 





on opioids is not the 
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outcome of infants 
exposed to opiate 
in-utero 













outcome in infants 
with NAS. 33 opiate-
exposed infants who 
were identified after 
development of 








The management of 
heroin misuse in 
pregnancy: time for 








There is increasing 
evidence of adverse 
effects upon 
developing cortical 
and visual function 
in children of treated 
heroin-addicted 
mothers. Studies 
are needed which 
take into account 
longer-term 
outcomes for the 
child. 
16 
The cost of crime 













were measured in 
439 pregnant 








facilities. The cost of 
the treatment facility 
was more than 
covered by the cost-














outcome in pregnant 
opiate-dependent 
women.  












in an enhanced 
programme were 
compared to those 

























outcomes of 367 
opiate-dependent 
women were 
compared to 215 
non-drug dependent 
women. The groups 
were further divided 




care. Infant mortality 
was reduced in the 
opiate-dependent 





















  Patient A Patient B Patient C Patient D Patient E Patient F 
Age 24 yrs 37 yrs 21 yrs 34 yrs 17 yrs 28 yrs 
Ethnicity Coloured Coloured Coloured White Coloured Coloured 
Marital status Divorced Single Single Single Single Married 
Gestational 
age 37+wks 33 wks 42+wks 39 wks 38+wks 36 wks 




































clinic visit  











Alcohol use no no no no no no 
Nicotine use yes yes no no yes yes 
Other 
substance use Heroin 
Heroin, 













































































Date last used 27/10/2009 04/06/2008 22/05/2010 21/04/2010 28/07/2009 09/03/2010 
Medical 












date 27/10/2009 05/06/2008 24/05/2010 16/06/2010 11/08/2009 23/03/2010 
Methadone 
administration 







































APGAR score 8/10, 10/10 7/10, 9/10 9/10, 10/10 9/10, 10/10 8/10, 10/10 09/10, 09/10 
Sex female male male female male female 
Birth weight 2.26 kgs 2.11 kgs 3.96 kgs 2.60 kgs 3.54 kgs 3.24 kgs 
Head 
Circumference 33cm 34cm 36cm 31cm 33cm 34cm 
Resus 
required none none none none none none 
Neonatal 
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